Table 1.
The clinical trials of MSCs-EVs
| Sources | Diseases | Intervention | N. Pats | Follow up | State | Location | Number/Ref. |
|---|---|---|---|---|---|---|---|
| BM-MSCs | Bronchopulmo-nary Dysplasia | Bone marrow mesenchymal stem cell-derived extracellular vesicles | 18 | 40 weeks | Recruiting | Boston Children’s Hospital Boston, Massachusetts, United States Brigham and Women’s Hospital Boston, Massachusetts, United States (and 3 more…) | NCT03857841 |
| BM-MSCs | Coronavirus | 5 times aerosol inhalation of MSCs-derived exosomes (2.0*10E8 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5) | 30 | 3.5 months | Not yet recruiting | Ruijin Hospital, shanghai, China | NCT04276987 |
| UC-MSCs | Chronic kidney disease | Umbilical cord MSC-EVs (100 μg/kg/dose) | 20 | 1 year | Concluded | Sahel Teaching Hospital Sahel, Cairo, Egypt | [109] |
| UC-MSCs | Macular degeneration | Cord tissue MSC-EVs injected directly around macular hole | 44 | 24 weeks | Recruiting | Tianjin Medical University Hospital Tianjin, China | NCT03437759 |
| UC-MSCs | Dry Eye | Umbilical mesenchymal stem cells derived Exosomes | 27 | 12 weeks | Recruiting | Zhongshan Ophthalmic Center Guangzhou, Guangdong, China | NCT04213248 |
| UC-MSCs | Diabetes mellitus Type 1 | Two doses of MSC-EVs | 20 | 3 months | Unknown | Sahel Teaching Hospital Sahel, Cairo, Egypt | NCT02138331 |
| AD-MSCs | Osteoarthritis | Secretome from adipose-derived mesenchymal stromal cells | 24 | 3 years | Not yet recruiting | / | NCT04223622 |